Reverse Design toward Optimized Labeled Chemical Probes - Examples from the Endocannabinoid System.

Academia–industry collaboration Chemical probe Drug discovery Endocannabinoid system Reverse design

Journal

Chimia
ISSN: 0009-4293
Titre abrégé: Chimia (Aarau)
Pays: Switzerland
ID NLM: 0373152

Informations de publication

Date de publication:
25 May 2022
Historique:
received: 14 04 2022
accepted: 16 04 2022
medline: 25 5 2022
pubmed: 25 5 2022
entrez: 9 12 2023
Statut: epublish

Résumé

Labeled chemical probes are of utmost importance to bring drugs from the laboratory through the clinic and ultimately to market. They support and impact all research and discovery phases: target verification and validation; assay development; lead optimization; and biomarker engagement in the context of preclinical studies and human trials. Probes should display high potency and selectivity as well as fulfill specific criteria in connection with absorption, distribution, metabolism, excretion and toxicology (ADMET) profile. Progress in fields such as imaging and proteomics increased the need for specialized probes to support drug discovery. Labeled probes carrying an additional reporter group are valuable tools to meet specific application requirements, but pose significant challenges in design and construction. In the reverse-design approach, small molecules previously optimized in medicinal chemistry programs form the basis for the generation of such high-quality probes. We discuss the reverse design concept for the generation of labeled probes targeting the endocannabinoid system (ECS), a complex lipid signaling network that plays a key role in many human health and disease conditions. The examples highlighted include diverse reporter units for a range of applications. In several cases the reported probes were the product of mutually rewarding and highly cross-fertilizing collaborations among academic and industry research programs, a strategy that can serve as a blueprint for future probe generation efforts.

Identifiants

pubmed: 38069714
doi: 10.2533/chimia.2022.425
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

425-434

Informations de copyright

Copyright 2022 Mónica Guberman, Miroslav Kosar, Anahid Omran, Erick M. Carreira, Marc Nazaré, Uwe Grether. License: This work is licensed under a Creative Commons Attribution 4.0 International License.

Auteurs

Mónica Guberman (M)

Leibniz-Forschungsinstitut für Molekulare Pharmakologie FMP, Campus Berlin-Buch, 13125 Berlin, Germany. Guberman@fmp-berlin.de.

Miroslav Kosar (M)

Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Vladimir-Prelog-Weg 3, 8093 Zürich, Switzerland. miroslav.kosar@org.chem.ethz.ch.

Anahid Omran (A)

Leibniz-Forschungsinstitut für Molekulare Pharmakologie FMP, Campus Berlin-Buch, 13125 Berlin, Germany. Omran@fmp-berlin.de.

Erick M Carreira (EM)

Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Vladimir-Prelog-Weg 3, 8093 Zürich, Switzerland. erickm.carreira@org.chem.ethz.ch.

Marc Nazaré (M)

Leibniz-Forschungsinstitut für Molekulare Pharmakologie FMP, Campus Berlin-Buch, 13125 Berlin, Germany. nazare@fmp-berlin.de.

Uwe Grether (U)

Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. uwe.grether@roche.com.

Classifications MeSH